GlassScriptPhysician profile
Vashtie Ramjattan
NPI 1619398948
$5,705.00
in general payments reported to CMS, 2019-2025
31 companies · $1,051 in 2025
The $1,051 reported for 2025 was more than what 88% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $778 · 2022: $703 · 2023: $1,081 · 2024: $2,092 · 2025: $1,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,444 · Travel and Lodging: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,444.08 |
| Travel and Lodging | $779.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,192.74 | 2021-2025 | Watchman Access System, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $574.88 | 2021-2024 | Eliquis, Camzyos |
| Abbott Laboratories | $447.89 | 2023-2025 | Aveir, Merlin@Home, Jot Dx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $292.51 | 2022-2025 | Lifevest |
| Medtronic, INC. | $283.67 | 2021-2024 | Linq II, Micra, Mycarelink |
| Astrazeneca Pharmaceuticals LP | $273.20 | 2021-2025 | Wainua, Farxiga |
| Abiomed | $234.26 | 2023-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.04 | 2022-2024 | Jardiance |
| Edwards Lifesciences Corporation | $159.20 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lantheus Medical Imaging, INC. | $123.91 | 2023-2025 | Definity |
| Alnylam Pharmaceuticals INC. | $114.18 | 2024-2025 | Amvuttra, Onpattro |
| Merck Sharp & Dohme LLC | $102.38 | 2021-2023 | Verquvo |
| Pfizer INC. | $89.78 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $87.89 | 2021-2022 | |
| Cvrx, INC. | $66.12 | 2024-2025 | Barostim Neo System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $59.26 | 2024-2025 | Carto 3 |
| Kestra Medical Technology Services, INC. | $52.51 | 2025 | Assure Wcd |
| Scpharmaceuticals INC. | $51.53 | 2024-2025 | |
| Esperion Therapeutics, INC. | $43.93 | 2021-2024 | Nexletol |
| Amgen INC. | $43.79 | 2021-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $34.19 | 2024 | |
| Csl Behring | $31.47 | 2022 | |
| Amarin Pharma, INC. | $28.34 | 2021 | |
| Atricure, INC. | $21.45 | 2024 | |
| Impulse Dynamics (USA) INC. | $20.69 | 2025 | Optimizer |
| Chiesi USA, INC. | $18.67 | 2025 | Kengreal |
| Daiichi Sankyo INC. | $17.00 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $15.51 | 2024 | Arcalyst |
| La Jolla Pharmaceutical Company | $14.52 | 2024 | Giapreza |
| Sanofi-Aventis U.S. LLC | $13.70 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vashtie Ramjattan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.